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OBJECTIVES: Allergic eosinophilic esophagitis (AEE) is characterized by intense eosinophilic inflammation of the
esophageal mucosa. Cysteinyl leukotrienes (CysLT) are eosinophil chemoattractants. We studied
CysLT levels in esophageal mucosa of children with AEE and controls.
METHODS: CysLT levels (pg CysLT/μg protein) were quantified by Enzyme-linked Immunosorbent Assay (ELISA)
on endoscopically obtained esophageal mucosal biopsies.
RESULTS: Twelve children with AEE (eight boys, mean age 6.6 yr, range 1.0–14.5 yr) and 10 controls (six boys,
mean age 9.56 yr, range 1.08–15.08 yr) were enrolled. None were on anti-LT or corticosteroid
therapy. All controls had histologically normal mucosal biopsies of the esophagus, stomach, and
duodenum. Patients with AEE had intense eosinophilic inflammation of the esophageal mucosa
(mean 39 eosinophils/hpf, range 15–70 eosinophils/hpf) and a normal 24-h pH probe study. CysLT
levels were similar between the two groups: mean levels were 12.44 (median 10.87, range
2.54–28.29) in AEE patients and 9.52 (median 9.26, range 1.71–21.64) in controls. CysLT levels did
not correlate with the degree of esophageal eosinophilic inflammation. Incidentally, five patients
with eosinophilic gastroduodenitis, in addition to esophagitis, were enrolled; their CysLT levels were
statistically higher than those of controls.
CONCLUSIONS: This is the first study to examine CysLT levels in esophageal mucosal biopsies of children with AEE
and normal children. CysLT levels in AEE patients are similar to those in controls, and independent
of the severity of inflammation. While this would argue against the use of CysLT antagonists in the
treatment of AEE, further studies into the expression of the CysLT receptor itself are needed.
(Am J Gastroenterol 2006;101:1125–1128)
INTRODUCTION
Allergic eosinophilic esophagitis (AEE) is an emerging, in-
completely understood disease. It is being increasingly en-
countered in children of all ages and in adults (1–3). The
initial descriptions of this entity date back to the 1970s (1)
though wider appreciation of this disease occurred in the mid-
to late 1990s, following the experience of Kelly et al. (2)
who fed an elemental diet to 10 children with eosinophilic
esophagitis. All 10 patients demonstrated symptomatic re-
sponse and attenuation of the eosinophilic inflammation.
The diagnostic criteria of AEE are now established and
include presence of ≥15 eosinophils/hpf on esophageal mu-
cosal biopsies and absence of pathological gastroesophageal
reflux on 24-h continuous monitoring of intraesophageal pH
(4). Vertical lines in the esophageal mucosa, circular rings in
the esophagus, and white material adherent to the esophageal
mucosa are endoscopic findings highly suggestive of AEE (5,
6). The treatment options for AEE are limited and include cor-
ticosteroids (either systemic or topical) and an elemental diet
(2, 7–10). Patients may suffer disease relapse on discontin-
uation of therapy (2, 7). Long-term use of these therapies is
unattractive, as these can be exacting on the patient and fami-
lies (i.e., elemental diet), or potentially associated with com-
plications (i.e., chronic corticosteroid use). Untreated AEE
can progress to esophageal strictures and small-caliber esoph-
agus, in addition to persistence of symptoms. There is an acute
need to identify alternate long-term maintenance therapeutic
agents that are patient-safe and effective.
Leukotrienes (LTs) are lipid mediators generated from
arachidonic acid, a normal constituent of the phospholipid
bilayer of biological membranes. Activation of mast cells,
eosinophils, and macrophages causes synthesis of cysteinyl
leukotrienes (CysLTs) that are proinflammatory mediators
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and eosinophil chemoattractants (11, 12). It has been sug-
gested that anti-LT agents, such as montelukast, a CysLT re-
ceptor antagonist that attenuates airway eosinophilia, may be
used to treat AEE (13–15). Levels of CysLT in the esophageal
mucosa have, however, not been previously reported.
We hypothesized that elevated CysLT levels in AEE would
support the use of CysLT receptor antagonists in the treat-
ment of children with AEE. In this pilot study, we measured
the levels of CysLT in esophageal mucosa of children with
AEE and controls in order to examine our hypothesis and to
generate questions for future research.
METHODS
Patients
Patients between the ages of 1 and 18 yr who underwent
esophagogastroduodenoscopy through the Division of Pedi-
atric Gastroenterology at the James Whitcomb Riley Hospital
for Children, Indiana University School of Medicine, Indi-
anapolis, IN were prospectively considered for the study. We
recruited controls (normal endoscopic and histologic appear-
ance of the upper gastrointestinal tract) and patients with
AEE (who had ≥15 eosinophils/hpf on esophageal mucosal
biopsies with normal biopsies of the gastric and duodenal
mucosa).
Two esophageal biopsies were endoscopically obtained for
CysLT analysis. These were snap frozen in liquid nitrogen
and stored at −70◦C. The study was approved by the Indi-
ana University/Clarian Health Partners Institutional Review
Board and all subjects provided written consent.
CysLT Expression
Endoscopically obtained esophageal mucosal biopsies were
homogenized and lipids were purified using the Sep-pak ex-
traction procedure as previously described (16). CysLT lev-
els, i.e., LTC4, LTD4, and LTE4, were quantified using kits
obtained from Cayman Chemicals (Ann Arbor, MI). The av-
erage of duplicate determinations was calculated and the re-
sult expressed as pg CysLT/μg protein for each sample.
Statistical Methods
The values for each group are expressed as the mean, median,
and range. Statistical analysis was performed utilizing Sig-
maStat software, version 2.03, from SPSS, Inc. (Chicago, IL).
Analysis between the two groups for the analytic assays was
performed by unpaired 2-tailed Student’s t-test. A p-value of
less than 0.05 was considered significant.
RESULTS
Ten controls (six boys, mean age 9.56 yr, median age 9.37 yr,
range 1.08–15.08 yr) and 12 children with AEE (eight boys,
mean age 6.6 yr, median age 5.79 yr, range 1.0–14.5 yr) were
studied (Table 1). None of the children were on anti-LT or
corticosteroid therapy. All controls had histologically normal
Table 1. Clinical Data on Study Patients
Controls AEE EEG
(N = 10) (N = 12) (N = 5)
Mean age (yr) 9.56 6.6 7.82
Age range (yr) 1.08–15.08 1.0–14.5 3.5–13.92
Male 6 (60%) 8 (66%) 4 (80%)
Symptoms
Vomiting 2 6 1
Abdominal pain 5 3 1
Dysphagia 2 3 1
Eructation – – 1
Heartburn – – 1
No. of eosinophils, mean (range)
Esophagus 0 39 (15–70)36 (20–60)
Stomach 0 0 42 (25–60)
Allergy data
No. of patients with atopy 3 5 3
Allergic rhinitis∗ 1 2 1
Asthma∗ 2 4 2
Eczema∗ – 1 1
Family history of atopy 1 3 2
Elevated serum IgE level† 0/0 3/9 1/3
Peripheral blood 0/9 8/11 4/5
eosinophilia†
Skin test positive† 1/1 8/9 4/5
∗Some patients had >1 atopy.
†Both the denominator and numerator are reported as not all patients had all studies
performed.
mucosal biopsies of the esophagus, stomach, and duodenum.
Patients with AEE had intense eosinophilic inflammation of
the esophageal mucosa (mean 39 eosinophils/hpf, range 15–
70 eosinophils/hpf), histologically normal gastric and duode-
nal mucosal biopsies, and an absence of pathologic gastroe-
sophageal reflux on 24-h pH probe study.
CysLT levels were measured in esophageal mucosal biop-
sies and were similar between controls and AEE patients. The
mean CysLT levels (pg CysLT/μg protein) were 9.52 (median
9.26, range 1.71–21.64) in controls and 12.44 (median 10.87,
range 2.54–28.29) in AEE patients ( p = 0.56). CysLT levels
did not correlate with the degree of esophageal eosinophilic
inflammation.
During the course of this prospective study, we had
five patients (four boys, mean age 7.82 yr, median age
8.42 yr, range 3.5–13.92 yr) whose biopsies revealed
more widespread inflammation of the upper gastrointestinal
tract. All five patients had intense eosinophilic esophagitis
and concomitant moderate-to-severe eosinophilic gastritis/
duodenitis, and were grouped as “eosinophilic esophago-
gastroduodenitis (EEG).” None of the patients were on anti-
LT therapy. They each had intense eosinophilic inflammation
of the esophageal mucosa (mean 36 eosinophils/hpf, range
20–60 eosinophils/hpf) and moderate-to-severe eosinophilic
gastritis; two of the four patients had moderate eosinophilic
duodenitis. All had an absence of pathologic gastroe-
sophageal reflux on 24-h pH probe study. Mean CysLT lev-
els in the esophageal mucosal biopsies of EEG patients were
33.62 (median 23.61, range 2.54–96.94); these were signifi-
cantly different from CysLT levels in controls ( p = 0.016).
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DISCUSSION
In this study we measured the levels of CysLT in esophageal
mucosal biopsies in order to examine the role of LT in the
pathogenesis of AEE. LT are 5-lipoxygenase metabolites of
the 20-carbon unsaturated fatty acid arachidonic acid pro-
duced by various cells, including mast cells, macrophages,
and eosinophils (11, 12). The 5-lipoxygenase pathway forms
two classes of LT, the nonpeptide LT, namely LTB4, and
the CysLT, namely LTC4, LTD4, and LTE4. LTC4 is ac-
tively transported extracellularly where subsequent cleav-
age of amino acids yields LTD4 and LTE4. CysLTs activate
CysLT receptors 1 and 2 (CysLT1 and CysLT2) and generate
the various biological effects associated with CysLT (17).
CysLTs are proinflammatory mediators and eosinophil
chemoattractants. They inhibit apoptosis and promote
eosinophil survival. Inhalation of LTD4 increases airway
eosinophils in asthmatics via a putative direct chemotactic
effect on eosinophils (12). CysLT expression is upregulated
in asthmatics and in infants with bronchopulmonary dys-
plasia and cystic fibrosis (12). LTD4, an extremely potent
eosinophil chemoattractant, is thought to also be released
from eosinophils within the gut wall. This dual action helps
it perpetuate and sustain eosinophilic inflammation (18).
CysLT1 receptor antagonists, like montelukast, zafirlukast,
and pranlukast, attenuate the number of eosinophils present
in the airway, sputum, and peripheral blood of asthmatics,
suppress the release of inflammatory mediators, and diminish
further recruitment of proinflammatory cells (19–21). These
drugs are widely and safely used in the treatment of asthma
(19, 22).
Montelukast has been reported to benefit patients with
eosinophilic inflammation of the gastrointestinal tract, but
the data are incomplete/unclear. In a recent report, mon-
telukast was used to symptomatically manage two young
adults with eosinophilic gastroenteritis—one had serosal
eosinophilic gastroenteritis diagnosed by paracentesis and
the other had eosinophilic inflammation on biopsies obtained
during colonoscopy (13, 19). In another case report, mon-
telukast dramatically reduced peripheral eosinophilia but not
mucosal eosinophilia in a patient with eosinophilic gastroen-
teritis (23).
Vanderhoof et al. (14) recently described the use of mon-
telukast in eight children with eosinophilic inflammation of
various parts of the gastrointestinal tract. All eight patients,
four of whom had eosinophilic inflammation of the esopha-
gus, had resolution of symptoms within a month of initiation
of therapy. It was not reported if any of these patients had en-
doscopic reevaluation performed. Recently, montelukast was
used to treat eight adults with AEE. All patients had a symp-
tomatic response but in none did the eosinophilic inflamma-
tion subside on repeat histological studies (15). Friesen et al.
(21) reported the use of montelukast in children with duode-
nal eosinophilia. A symptomatic benefit was noted but repeat
endoscopic evaluation was not performed. Anecdotal experi-
ence suggests that patients with AEE may be asymptomatic
in the face of intense histological abnormalities, and may re-
port symptom resolution/improvement with acid-suppressive
therapy without histological improvement (24). These expe-
riences emphasize the inadequacy of subjective end points in
meaningfully evaluating the course of this disease. Instead,
more objective criteria rather than patient-reported symptom
assessment should be employed to assess the efficacy of ther-
apeutic interventions in patients with AEE.
In this pilot study, we did not find a difference in the levels
of CysLT between controls and patients with AEE. A num-
ber of variables may have negatively affected the findings.
The severity of esophageal inflammation may be patchy in
AEE patients and may result in sampling error. The number
of patients in this pilot study could have contributed to the
sampling error. The Enzyme-linked Immunosorbent Assay
(ELISA) technique is quantitative and in previous studies in
patients with idiopathic pulmonary fibrosis, it has been able
to detect 5- to 10-fold differences in CysLT levels in lung tis-
sue compared with controls (25). To minimize the possibility
of technique variability, all samples were run as one batch.
Our limited data in a small group of patients with EEG
are suggestive of possible overproduction of CysLTs in pa-
tients with eosinophilic inflammation that extends beyond the
esophagus. This finding might explain why patients with EEG
are reported to benefit from CysLT1 receptor antagonists (13,
18, 21, 23). While this requires more definitive exploration
in a larger patient sample, it does raise interesting questions
about possible distinctions between these disorders. It is plau-
sible that AEE is a distinct disorder from other eosinophilic
inflammatory conditions of the gastrointestinal tract, includ-
ing EEG.
In summary, this is the first study to examine CysLT levels
in esophageal mucosal biopsies of children with AEE and
normal children. Our results indicate that CysLT expression
in AEE patients is similar to that in controls and independent
of the severity of inflammation. While this would suggest
against the use of CysLT antagonists in the treatment of AEE,
it is plausible that a subset of AEE patients may benefit from
these drugs. In our ongoing and future studies we intend to
study a larger number of patients, both with AEE and with
EEG, and examine biopsies of their upper gastrointestinal
tracts for the expression of the CysLT receptor itself. We
feel it will be worthwhile to perform immunohistochemistry
studies on these tissue samples to help identify the cellular
source of CysLT. The results may further clarify the utility
of this class of drugs in the management of AEE/EEG and
also help define the role of mast cells and macrophages in the
inflammation associated with AEE/EEG.
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STUDY HIGHLIGHTS
What is New Here Allergic eosinophilic esophagitis (AEE) is an emerging
and increasingly recognized condition in children and
adults. Activation of eosinophils induces synthesis of cys-
teinyl leukotriene (CysLT), promoting inflammation
and eosinophil infiltration.
What Is Current Knowledge Cysteinyl leukotriene (CysLT) levels in esophageal
mucosa of children with eosinophilic esophagitis are
similar to those in controls. Children with more wide-spread eosinophilic inflam-
mation of the upper gastrointestinal tract have higher
mucosal levels of CysLT than controls. CysLT antagonist drugs such as montelukast may not
be as efficacious in eosinophilic esophagitis as is hoped.
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